Browse:

InMed Technologies is committed to research and drug discovery. We believe we can make a difference; we have devoted vast resources to discover and develop the highest quality, innovative and specific nutraceuticals, nutritional supplements and cosmeceuticals.

Research can be conducted in a number of different ways for many different purposes, from clinical trial studies in large patient populations to bioavailability studies on absorption in humans. Research must have controls and baseline rates to show correlations of benefit and effectiveness. Research also needs to have safety mechanisms and professionals conducting the research to be highly experienced.

Regardless of whether a research program is on a nutraceutical or pharmaceutical product, the research protocols and stringent controls must be the same.

Research focus at InMed Technologies

Some may argue that nutraceutical research does not need the same controls as pharmaceutical research, because it is generally safe or natural. However, human bioindividuality shows us that people may or could react differently.

Being able to conduct scientific and medical research allows InMed Technologies to safely innovate. It also allows us to educate our clients, which in turn ensures confidence in the clinic.

InMed Technologies is partly owned by an Australian company, Medlab (www.medlab.co), a certified biological research center, specializing in the development of novel therapeutics from bacteria. Professor Luis Vitetta heads Medlab’s research, a peer reviewed, invitational speaker renowned for his work in probiotics and gut health. Professor Vitetta is partnered with David Rutolo, PhD, senior officer at InMed Technologies, a renowned expert in small particle absorption (patent holder), and product fabrication.

This partnership allows InMed Technologies to conduct research under the rigors of pharmaceutical development. InMed Technologies patent portfolio is an outcome of research, allowing us to strongly differentiate ourselves from other companies. We believe we can serve the needs of healthcare professionals and patients better than anyone else in the business.

Scholoss, J, Vitetta L. Antioxidants to Abrogate Free Radicals: a billion dollar industry based on a chimeric notion without biological plausibility. New insights to challenge currently held beliefs. Australian Journal of Herbal medicine 2014;26(1):4-6, 33.

Vitetta L. The gastrointestinal tract microbiome and the metabolism of herbal compounds such as trigonella foenum-graecum extract. The 4th International Symposium on Curry and Spice (April 24, 2014) in Seoul, South Korea.